- Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial2018 | Second Faculty of Medicine
- Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy2018 | First Faculty of Medicine
- Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor2019 | Second Faculty of Medicine
- Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study2012 | Second Faculty of Medicine
- Features and outcome of chronic myeloid leukemia at very young age: Data from the International Pediatric Chronic Myeloid Leukemia Registry2021 | Second Faculty of Medicine
- Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial2018 | Second Faculty of Medicine
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial2018 | Publication without faculty affiliation